1. Home
  2. BTCT vs TCRT Comparison

BTCT vs TCRT Comparison

Compare BTCT & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTCT

BTC Digital Ltd.

SELL

Current Price

$0.56

Market Cap

7.5M

Sector

Real Estate

ML Signal

SELL

Logo Alaunos Therapeutics Inc.

TCRT

Alaunos Therapeutics Inc.

SELL

Current Price

$1.60

Market Cap

7.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BTCT
TCRT
Founded
2006
1998
Country
Singapore
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
7.8M
IPO Year
2019
2025

Fundamental Metrics

Financial Performance
Metric
BTCT
TCRT
Price
$0.56
$1.60
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
253.5K
★ 1.6M
Earning Date
11-27-2026
11-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 24.66
EPS
★ N/A
N/A
Revenue
N/A
★ $15,900,000.00
Revenue This Year
$1.58
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$0.72
52 Week High
$2.75
$4.50

Technical Indicators

Market Signals
Indicator
BTCT
TCRT
Relative Strength Index (RSI) 34.27 44.64
Support Level $0.50 $1.61
Resistance Level $1.21 $2.09
Average True Range (ATR) 0.06 0.17
MACD 0.01 -0.07
Stochastic Oscillator 4.48 10.16

Price Performance

Historical Comparison
BTCT
TCRT

About BTCT BTC Digital Ltd.

BTC Digital Ltd is the ledger technology that underlies bitcoin and other cryptocurrencies, based in the U.S., with a focus on bitcoin mining. A blockchain is a decentralized, distributed, and encrypted digital public ledger that stores information in a secure, verifiable, and permanent way. The company also generates revenue through the resale of mining machines, mining machine rental, and miner hosting services.

About TCRT Alaunos Therapeutics Inc.

Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.

Share on Social Networks: